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Ulcerative colitis (UC) has a major impact on the quality of life (QoL) of
affected patients. Patient-reported outcomes have not been thoroughly
evaluated in patients with UC receiving oral mesalazine (mesalamine).
Aim
To examine the effect of mesalazine on QoL of patients with mildly
and moderately active UC and assess the time course of change,
baseline disease severity, mesalazine dose and responder status on
QoL parameters.
Methods
Inflammatory Bowel Disease Questionnaire (IBDQ) data were combined
from two double-blind, randomized, multicentre, active-controlled trials
assessing 2.4 and 4.8 g ⁄day oral delayed-release mesalazine in 687
patients. Mean score changes from baseline were compared at 3 and
6 weeks and effects of baseline severity, mesalazine dose and response
to therapy were examined.
Results
Mesalazine significantly improved IBDQ scores at 3 and 6 weeks (mean
increase, 29.6 and 39.7 points, respectively; P < 0.0001 for both).
Improvement was greater for patients with moderate disease. Greater
week 6 changes occurred in clinical responders than nonresponders
(50.1 vs. 23.6 points, respectively; P < 0.0001).
Conclusions
Delayed-release oral mesalazine produces significant clinical and statis-
tical improvements in QoL of patients with UC by 3 weeks, with further
improvement at 6 weeks.
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INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD), the
two major inflammatory bowel diseases (IBDs), are
chronic relapsing conditions that result in debilitating
gastrointestinal symptoms and important changes in
patients’ quality of life (QoL).1, 2 Although the main
factors that affect QoL in patients with UC appear to
be severity of symptoms and the effectiveness of med-
ical or surgical therapies, psychosocial and demo-
graphic factors are also important. For example, the
greatest impact of UC on QoL occurs in females,
African-American patients and those with lower socio-
economic status.3 QoL has also been reported to be
worse in patients who have undergone surgery and
those with a diagnosis of CD rather than UC.1, 4
General QoL assessment tools, such as the Short
Form 36, although well validated in many languages
and with published population norms, may be limited
in their ability to detect clinically important improve-
ments or deteriorations that are most relevant to
patients with a particular condition. They are best sui-
ted for comparing different populations or different
disease conditions, or detecting unanticipated out-
comes. Disease-specific instruments have been devel-
oped to assess health-related QoL in patients with a
single chronic disease [e.g. IBD, gastro-oesophageal
reflux disease, irritable bowel syndrome (IBS)] and
have been shown to reflect QoL in patients with a par-
ticular condition.5–7
The Inflammatory Bowel Disease Questionnaire
(IBDQ) has been shown to be a valid, reliable and
responsive tool for assessing QoL in patients with
IBD.8, 9 Cohort studies and clinical trials in CD have
shown strong inverse correlations between the Crohn’s
Disease Activity Index and the IBDQ (r = approxi-
mately )0.7) and have examined the important score
thresholds corresponding to clinical remission and
response.8, 9 The IBDQ scores for patients in remission
typically are ‡170 and increases in the total IBDQ
score of 16–32 points (or at least 0.5–1.0 point for
each question) are generally considered to be associ-
ated with a significant improvement in QoL.5, 8, 9 In
addition, a study of patients with UC by Higgins
et al.10 suggested that an increase of more than 20
points in the total IBDQ score was associated with
patient-defined significant improvement. In UC,
Feagan et al.11 analysed data from the Active Ulcera-
tive Colitis Trials 1 and 2 (ACT 1 and ACT 2) and
found that patients with moderate-to-severe UC
(defined by a Mayo score of 6–12) treated with inflix-
imab 5 or 10 mg ⁄ kg for 8 weeks had improvements in
their mean (s.d.) IBDQ scores of 36 (34) or 40 (34)
points compared with 21 (28) points among placebo-
treated patients (P < 0.005 for comparisons vs.
placebo).
To date, no large trials have assessed the effect of
mesalazine (mesalamine) therapy on QoL or patient-
reported outcomes in mildly and moderately active
UC. Therefore, we examined combined QoL data from
two previously published randomized, active-
controlled trials [Assessing the Safety and Clinical
Efficacy of a New Dose of 5-aminosalicylic acid (5-
ASA; ASCEND I and ASCEND II)].12, 13 These trials
evaluated the efficacy and safety of delayed-release
oral mesalazine 4.8 g daily (investigational 800-mg
tablet) vs. that of 2.4 g daily (Asacol 400-mg tablet;
Procter & Gamble Pharmaceuticals, Inc., Mason, OH,
USA) in patients with mildly and moderately active
UC. Our aims were to examine (i) the effect of mesal-
azine therapy on QoL in patients with mildly and
moderately active UC as measured by the IBDQ, (ii) the
time course of QoL changes after treatment; and (iii)
whether baseline disease severity, dose of mesalazine
or degree of clinical response would predict changes
in the IBDQ.
METHODS
Background on ASCEND studies
The ASCEND I and II trials were two separate multi-
centre, randomized, double-blind, active-controlled tri-
als comparing oral delayed-release mesalazine given
at doses of 4.8 g ⁄ day (using an investigational 800-
mg tablet) and 2.4 g ⁄ day (dosed with the currently
marketed Asacol 400-mg tablet) in patients with
mildly and moderately active UC. Details of the study
design and methods have been previously published
elsewhere.12, 13 These studies were similar in terms of
design, eligibility criteria, interventions and primary
and secondary end points assessed. Patients 18–
75 years of age with a diagnosis of UC confirmed
within the past 24 months by endoscopy or radiogra-
phy were eligible for inclusion in these trials. Patients
were randomized to receive a 6-week course of one of
the two dosing regimens noted above and were
assessed at baseline, week 3 and week 6. Disease
severity was assessed by the physician’s global assess-
ment (PGA) score, which included evaluation of stool
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frequency, rectal bleeding, endoscopic findings and
the patient’s functional assessment (PFA). The primary
end point was the proportion of patients in each treat-
ment group who achieved overall improvement. Over-
all improvement (‘treatment success’) was defined as
improvement in PGA and improvement in at least one
other clinical assessment parameter (stool frequency,
rectal bleeding, endoscopy or PFA), with no worsening
in any of the remaining clinical assessments.
Collection of QoL data with IBDQ
The IBDQ was self-administered at each patient visit
(baseline, week 3 and week 6) and completed before
any clinical assessments were performed to avoid
introducing bias in patients’ responses. The IBDQ con-
sists of 32 items, each of which is scored on a seven-
point Likert scale where one reflects very poor QoL
and seven represents very good QoL. The questionnaire
examines four domains: bowel symptoms (10 items),
systemic symptoms (five items), emotional factors (12
items) and social factors (five items).8, 14, 15 Thus, pos-
sible scores range from 32 to 224, with a higher score
corresponding to better QoL. The total IBDQ scores
and scores from the four domains (bowel, systemic,
emotional and social) were calculated for each time
point. Data for patients missing more than four of 32
questions were not included in the analyses of total
score. Similarly, patients with more than one missing
response in a symptom domain were excluded from
the analyses for that domain. The criteria established
for inclusion in this IBDQ analysis meant that some
patients with substantial missing data were excluded
from the QoL analyses performed. Figure 1 depicts the
number of evaluable patients at each time point for
the IBDQ total score and each of the domain
subscores. A majority of patients with missing IBDQ
scores dropped out of the study because of voluntary
withdrawal, protocol violation, adverse events, investi-
gator recommendation or lack of treatment effect. The
overall number of dropouts was balanced between
treatment groups.
Statistical analysis
Data from the treatment arms of the two studies were
combined for the QoL analysis. A paired t-test was
used to analyse the change in IBDQ scores at weeks 3
and 6 compared to baseline. The effect of 5-ASA treat-
ment on QoL was analysed using analysis of variance
(ANOVA), with treatment and study protocol as predic-
tive factors. An ANOVA was performed comparing
changes in QoL outcomes between groups with mild
and moderate baseline severity and between respond-
ers and nonresponders.
RESULTS
A total of 687 patients with mildly or moderately
active UC were randomized in the two trials. Baseline
characteristics were similar in the two dosing groups
(Table 1). The mean baseline Ulcerative Colitis Disease
Activity Index (6.2; s.d., 1.91) and the mean baseline
IBDQ score (143; s.d., 35.17) were consistent with
active UC. Results related to the primary efficacy end
point of the two individual trials included in this anal-
ysis (ASCEND I and II) have been reported else-
where.12, 13 The results of the combined analysis are
consistent with the findings of the individual trials,
which showed an advantage for 4.8 g ⁄ day over
2.4 g ⁄ day in patients with moderately active UC. In
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574 evaluable577 evaluable 577 evaluableWeek 6
Figure 1. Evaluable subjects included in analyses of total IBDQ score and four symptom domain scores, by week. IBDQ,
Inflammatory Bowel Disease Questionnaire.
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occurred in 58% (184 ⁄ 318) of patients treated with
4.8 g ⁄ day compared to 53% (175 ⁄ 332) of patients
treated with 2.4 g ⁄ day (P = 0.1936). In moderately
active UC, 72% (144 ⁄ 200) of those receiving 4.8 g ⁄ day
(800-mg tablet) of delayed-release mesalazine
achieved the primary end point of overall improve-
ment at week 6 compared to 58% (130 ⁄ 223) of
patients receiving 2.4 g ⁄ day (400-mg tablet)
(P = 0.0034).16
Effect of mesalazine on IBDQ score in patients
with mildly to moderately active UC
Mesalazine treatment resulted in a significant
improvement from baseline in the mean total IBDQ
scores at 3 weeks, with further improvement observed
at 6 weeks. The mean (s.d.) change in the total IBDQ
score was 29.6 (29.86) at 3 weeks and 39.7 (35.20) at
6 weeks (P < 0.0001 vs. baseline for both time points;
Table 2). Mean total IBDQ scores increased from 142.8
points at baseline to 173.0 points at 3 weeks and
increased further to 183.9 points at 6 weeks. After
3 weeks of therapy, 58% of all randomized patients
had a greater than 20-point increase in total IBDQ
score from baseline, which, at 6 weeks, increased to
68%. Treatment was also associated with significant
improvements in all IBDQ domain components (bowel
symptoms, systemic symptoms, emotional function,
social function) at 3 and at 6 weeks (P < 0.0001 for all
comparisons vs. baseline). The greatest improvement
occurred in the bowel domain, which showed a mean
1.53-point improvement per item after 6 weeks of
treatment. Mean changes per item in the systemic,
emotional and social domains at week 6 were 1.17,
1.10 and 1.06 points, respectively. In addition, a statis-
tically significant incremental increase between 3 and
6 weeks was observed for total IBDQ and each individ-
ual IBDQ domain component (P < 0.0001).
Table 1. Baseline demographic characteristics
Parameter
Mesalazine
2.4 g ⁄ day
(n = 349)
Mesalazine












Female 186 (53.3) 181 (53.6) 367 (53.4)
Male 163 (46.7) 157 (46.4) 320 (46.6)
Race, n (%)
Caucasian 272 (77.9) 258 (76.3) 530 (77.1)
Non-Caucasian 77 (22.1) 80 (23.7) 157 (22.9)
Smoking history, n (%)
Never 198 (56.7) 182 (53.8) 380 (55.3)
Previously 120 (34.4) 126 (37.3) 246 (35.8)
Currently 31 (8.9) 30 (8.9) 61 (8.9)
Length of disease history, n (%)
<1 years 137 (39.3) 122 (36.1) 259 (37.7)
1–5 years 73 (20.9) 81 (24.0) 154 (22.4)
>5–10 years 59 (16.9) 59 (17.5) 118 (17.2)
>10 years 76 (21.8) 74 (21.9) 150 (21.8)
Unknown 4 (1.1) 2 (0.6) 6 (0.9)
Mean baseline UCDAI score (s.d.) 6.2 (1.93) 6.2 (1.89) 6.2 (1.91)
Mean baseline IBDQ total score (s.d.) 143.3 (35.12) 142.3 (35.28) 142.8 (35.17)
Mean bowel symptoms (IBDQ) score (s.d.) 41.5 (11.17) 41.4 (11.05) 41.4 (11.10)
Mean systemic symptoms (IBDQ) score (s.d.) 20.9 (6.26) 20.4 (6.30) 20.7 (6.28)
Mean emotional function (IBDQ) score (s.d.) 55.0 (14.35) 54.4 (14.34) 54.7 (14.34)
Mean social function (IBDQ) score (s.d.) 26.2 (8.08) 26.3 (7.74) 26.2 (7.91)
Mean duration of flare to first dose (s.d.), days 103.7 (141.75) 94.0 (103.93) 98.9 (124.48)
UCDAI, Ulcerative Colitis Disease Activity Index; IBDQ, Inflammatory Bowel Disease Questionnaire.
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Time course of QOL changes after treatment in
patients with mildly and moderately active UC
Figure 2 depicts the distribution of the mean IBDQ
scores at baseline, week 3 and week 6 during the
study. Improvement in IBDQ occurred rapidly, by week
3, with an additional increase noted at week 6. This
trend remained when IBDQ scores were analysed sepa-
rately for responders and nonresponders. Interestingly,
a small subset of patients failed to have large QoL
improvements, as seen in the leftward tails of Figure 2
at weeks 3 and 6. Attempts to identify baseline factors
that could predict those patients who would not
achieve IBDQ improvement with mesalazine (e.g.
female gender, older age or patients with severe scores
for IBS-like bowel items) were unsuccessful.
Effect of baseline severity on IBDQ score
improvement in patients with mildly and
moderately active UC
At study entry, 238 patients had mild disease and 448
had moderately active disease. One patient was
excluded from disease severity analysis because of a
missing baseline assessment. Table 3 lists the mean
(s.d.) total IBDQ scores reported at baseline, 3 weeks
and 6 weeks according to disease severity. As
expected, patients with moderately active disease had
a greater improvement in mean IBDQ scores after
treatment with delayed-release mesalazine than
did patients with mildly active disease. Patients with
moderately active disease achieved a mean (s.d.)
increase of 31.9 (29.61) points at 3 weeks and 43.8
(35.22) points at 6 weeks compared to an increase of
Table 2. Improvement in IBDQ
scores and subscores after treat-
ment at each visit
IBDQ













Total (32 items) 29.6* (29.86) 0.92* (0.93) 39.7* (35.20) 1.24* (1.10)
Bowel (10 items) 11.1* (11.40) 1.11* (1.14) 15.3* (12.76) 1.53* (1.28)
Systemic (5 items) 4.3* (5.21) 0.85* (1.04) 5.8* (6.17) 1.17* (1.23)
Emotional (12 items) 9.9* (11.09) 0.83* (0.92) 13.2* (13.39) 1.10* (1.12)
Social (5 items) 4.0* (6.12) 0.81* (1.22) 5.3* (7.02) 1.06* (1.40)
* P < 0.0001 from baseline.






















Baseline (n = 676)
Week 6 (n = 576)
Week 3 (n = 594)
Figure 2. Distribution (mountain plot) of total IBDQ
scores at baseline, week 3, and week 6 in patients with
mildly and moderately active UC. IBDQ, Inflammatory
Bowel Disease Questionnaire.
Table 3. Total IBDQ scores at each visit by disease
severity
Mean total IBDQ score (s.d.)
Baseline Week 3 Week 6
Mild disease
(n = 238)




136.7* (35.16) 169.6 (32.35) 181.9 (31.56)
* P < 0.0001 between-disease severity comparison.
 P = 0.0096 and  P = 0.0002 change from baseline vs.
mild disease.
IBDQ, Inflammatory Bowel Disease Questionnaire.
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25.6 (29.93) points at week 3 and 32.9 (34.15) points
at week 6 in patients with mildly active
disease (P = 0.0096 and P = 0.0002 at 3 and 6 weeks,
respectively).
Dose effect on IBDQ score improvement in
patients with mildly and moderately active UC
Quality of life improved independently of drug dose;
there were no significant differences between the 4.8-
and 2.4-g ⁄ day dosing regimens in mean total IBDQ
score or subscore changes. Patients receiving
4.8 g ⁄ day had a mean (s.d.) increase from baseline
IBDQ score of 30.8 (29.93) and 41.3 (33.48) points at
week 3 and week 6, respectively. Similar results were
observed in the patients receiving 2.4 g ⁄ day who
reported mean (s.d.) increases in IBDQ from baseline of
28.3 (29.79) points at week 3 and 38.1 (36.83) points
at week 6. Figure 3 shows the proportion of patients
who had different degrees of change in total IBDQ
score from baseline to Week 6 by dose. The majority
of patients (89%) had improved QoL; only 11% of
patients had no change or worsening in the total IBDQ
score.
Clinical response associated with IBDQ score
improvement in patients with mildly and
moderately active UC
A clinical response to therapy was defined as meeting
the predetermined primary study end point of overall
improvement described earlier. Patients who met the
criteria for clinical response experienced a signifi-
cantly greater mean increase in total IBDQ score than
did patients who did not respond to therapy. At week
3, clinical responders had a mean (s.d.) increase in
total IBDQ score of 38.7 (29.72) points compared to
22.2 (27.83) points in nonresponders (P < 0.0001).
Similarly, at 6 weeks, patients who responded to ther-
apy had a mean (s.d.) increase of 50.1 (33.61) points
compared to 23.6 (30.84) points in patients who did
not show overall improvement (P < 0.0001; Figure 4).
The total IBDQ score among clinical responders
increased from 141.4 points at baseline to 191.2 points
at week 6. In contrast, nonresponders had a mean
baseline score of 145.3 points that had increased to
only 172.7 point at the 6-week time point.
Although no differences were seen in the QoL
improvement between doses, there was a difference
noted between 4.8 and 2.4 g ⁄ day when patients were
grouped according to response to therapy. There was
no significant difference in the mean change from
baseline reported among clinical responders: 37.6
points [95% confidence interval (CI), 32.5–42.7] at
week 3 and 51.8 points (95% CI, 46.5–57.1) at week 6
for 2.4 g ⁄ day compared to 39.8 points (95% CI, 34.7–
44.9) at week 3 and 48.5 points (95% CI, 43.8–53.3) at
week 6 for 4.8 g ⁄ day (P = 0.36 at 6-week end point).
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Figure 3. Proportion of patients by mesalazine dose with
different degrees of change (histogram) in total IBDQ
score from baseline to week 6. IBDQ, Inflammatory Bowel
Disease Questionnaire. Total IBDQ score increases of 16–
32 points are associated with significant QoL improve-
ment.5 A study of patients with UC suggests that an































Figure 4. Overall improvement in total IBDQ scores by
clinical responders and nonresponders in patients with
mildly and moderately active UC. IBDQ, Inflammatory
Bowel Disease Questionnaire.
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In contrast, the 4.8-g ⁄ day dose appeared to be more
effective for QoL than did the 2.4-g ⁄ day dose among
nonresponders. Mean IBDQ scores improved by 23.8
points (95% CI, 19.4–28.2) at week 3 and 29.1 points
(95% CI, 22.9–35.2) at week 6 (P < 0.0001 vs. base-
line) in the 4.8-g ⁄ day group. Mesalazine 2.4 g ⁄ day
resulted in improvements of 20.5 points (95% CI,
16.2–24.8) at week 3 and 18.8 points (95% CI, 13.4–
24.2) at week 6 among nonresponders (P < 0.0001 vs.
baseline). The between-dose difference reached a
statistical significance with a P value of 0.01 at the
6-week time point.
Effects of individual study results
In each study, patients showed significant increases in
QoL at weeks 3 and 6 vs. baseline with delayed-release
oral mesalazine therapy regardless of dose or disease
severity. Table 4 lists the individual trial results of mean
(s.d.) total improvement and total IBDQ scores reported
at 6 weeks according to disease severity and dose.
DISCUSSION
This important combined analysis of a large study
population represents a major observation of QoL
improvement after treatment with mesalazine. The
results of this analysis indicate that treatment with
delayed-release oral mesalazine 2.4 or 4.8 g ⁄ day is
associated with a significant improvement in QoL in
patients with mildly or moderately active UC. The
improvement is evidenced by the change in the total
IBDQ scores as well as in each of the IBDQ domain
subscores at 3 weeks, with further improvement at
6 weeks. The mesalazine dose administered did not
affect the changes in IBDQ scores reported in our
study. The QoL response to mesalazine therapy is con-
sistent with clinically important improvement results
from previous trials in CD and UC. A review of recent
cross-sectional and cohort studies of QoL in UC
reported mean IBDQ scores ranging from 190 to 205
points for patients in remission, 184 points for those
with mild UC, 128–160 points for those with moderate
UC and 118 points for those with severely active UC.5
The patients in our trial had mean baseline scores of
143 points (Table 1), which is consistent with moderate
disease, and had largely improved by week 3 (Table 3).
Previous studies have noted that treatments that
improve the signs and symptoms of IBD can have a
positive impact on QoL and attempts have been made
to quantify this effect. Robinson et al.17 examined the
effects of mesalazine capsules (1, 2 and 4 g) or placebo
on 12 QoL parameters in patients with UC. These
included five disease-specific parameters (trips to the
toilet, stool consistency, rectal bleeding, abdomi-
nal ⁄ rectal pain and rectal urgency) and seven general
parameters (ability to sleep, sexual relations, routine
outdoor activities, social activities, indoor activities,
work ⁄ occupation and hobbies ⁄ recreation). Mesalazine
doses of 2 or 4 g produced statistically significant
Table 4. Mean total IBDQ
scores and score changes after
6 weeks in ASCEND I and
ASCEND II according to dis-
ease severity and mesalazine
dose
Baseline severity
ASCEND I ASCEND II
Mesalazine
2.4 g ⁄ day
(n = 154)
Mesalazine
4.8 g ⁄ day
(n = 147)
Mesalazine
2.4 g ⁄ day
(n = 195)
Mesalazine
4.8 g ⁄ day
(n = 191)
Mild and moderate (n = 687)
Mean change (s.d.) 37.3 (36.10) 45.6 (33.62) 38.9 (37.52) 38.2 (33.13)
Mean total score (s.d.) 187.2 (27.89) 187.4 (28.45) 180.6 (33.01) 181.9 (30.37)
Mild (n = 238)
Mean change (s.d.) 30.9 (32.87) 37.1 (31.31) 29.3 (38.78) 33.7 (34.31)
Mean total score (s.d.) 192.0 (26.20) 191.1 (24.16) 181.7 (31.79) 183.6 (27.93)
Moderate (n = 448)
Mean change (s.d.) 41.8 (37.81) 53.0 (34.02) 43.1 (36.32) 40.4 (32.48)
Mean total score (s.d.) 183.8 (28.69) 184.3 (31.49) 180.1 (33.67) 181.1 (31.57)
P < 0.0001 for all changes from baseline.
IBDQ, Inflammatory Bowel Disease Questionnaire; ASCEND, Assessing the Safety and
Clinical Efficacy of a New Dose of 5-aminosalicylic acid.
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improvements vs. baseline in all 12 parameters
(P < 0.02).
In the current combined analysis of the ASCEND I
and II mild-and-moderate UC data, an impressive 68%
of patients had a greater than 20-point increase from
baseline and 74% of patients achieved IBDQ scores of
‡170 points after 6 weeks of mesalazine treatment.
Significant changes in all subscores were also seen at
6 weeks. Thus, a majority of patients receiving mesal-
azine therapy in our study achieved IBDQ scores that
reflect remission cutoff values suggested by Hlavaty
et al.9 and had IBDQ improvements that are congruent
with other treatments for UC as reported by Feagan
et al.11 The improvement in IBDQ score observed
among treatment nonresponders is an interesting find-
ing. This finding could reflect respondent bias from
being in a clinical trial; however, it could also support
the IBDQ as a sensitive outcome measure for clinical
trials in UC. There is currently no standardized end
point for measuring or defining efficacy in UC clinical
trials. Commonly used end points include improve-
ment or remission, although the definition and results
can differ substantially between trials. The improve-
ment and dose response in QoL among nonresponders
may suggest that the IBDQ is able to detect subtle dif-
ferences in the disease course that may not be detected
by current end points used in UC clinical trials.
Although additional studies are needed to determine
whether IBDQ is more sensitive to small changes in
clinical status than are current clinical measures, these
results support the use of clinically important QoL
measures in UC clinical trials.
The similar study design and results of the ASCEND
I and II trials made it possible to combine the trial
data. Although the post hoc nature of this pooled QoL
analysis could be considered a methodological limita-
tion, this approach allowed examination of a large
population sample, most of whom had complete QoL
data. We did examine for differences by individual
study and found no significant differences.
In conclusion, treatment with delayed-release oral
mesalazine tablets significantly improved QoL in
patients with mildly and moderately active UC by
3 weeks of treatment and further improved QoL at
6 weeks of treatment. The daily mesalazine dose did
not predict the magnitude of QoL improvement. The
individual patient’s clinical response to therapy was a
predictor of improved QoL.
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